Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
| ▸ | APLNR | P35414 | 2/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124109 | 0.83 | PDCD1 (0.38) | PDCD1CD274 | |
| SCHEMBL24215353 | 0.83 | APLNR (0.35) | KMT2AHTTRECQLAPLNR | |
| SCHEMBL9606634 | 0.83 | PIK3CA (0.33) | KMT2AHTTRECQL | |
| SCHEMBL29333357 | 0.83 | HTT (0.33) | HTTRECQL | |
| SCHEMBL19407622 | 0.82 | P2RX3 (0.30) | — | |
| SCHEMBL30067748 | 0.82 | P2RX3 (0.36) | MAPTCASP1 | |
| SCHEMBL25911621 | 0.82 | P2RX3 (0.36) | HTTRECQLMAPTCASP1AURKA | |
| SCHEMBL84915 | 0.82 | P2RX3 (0.36) | MAPTCASP1 | |
| SCHEMBL30068288 | 0.82 | P2RX3 (0.36) | HTTRECQLMAPTCASP1AURKA | |
| SCHEMBL19407755 | 0.77 | CYP2C19 (0.33) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524906-B2 | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| CN-101547934-A | Process for selectively localizing active ingredients on and in mitochondria and corresponding active ingredients | UGICHEM GES FUER ORGANISCHE CH (AT) | 2009-09-30 | — | — | CN | disclosed |
| CN-101495505-A | Chiral compounds substituted with phosphonate ester or phosphonic acid | UGICHEM GMBH (AT) | 2009-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | KMT2A 2403/4885HTT 519/4885RECQL 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.